Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
MRX-5 is a novel benzoxazole antibiotic developed for the treatment of mycobacteria infections, particularly infections caused by non-tuberculous Mycobacteria
Infections with H. pylori affect over 43 percent of the world’s population with a wide range of gastrointestinal disorders
Merck will record a pre-tax charge relating to the upfront payment of $588 million
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
The trademark rights for these brands will be transferred to Lupin by March next year.
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Subscribe To Our Newsletter & Stay Updated
